GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (NAS:VTRS) » Definitions » Price-to-Owner-Earnings
中文

Viatris (Viatris) Price-to-Owner-Earnings : 10.79 (As of Apr. 25, 2024)


View and export this data going back to 1986. Start your Free Trial

What is Viatris Price-to-Owner-Earnings?

As of today (2024-04-25), Viatris's share price is $11.55. Viatris's Owner Earnings per Share (TTM) ended in Dec. 2023 was $1.07. It's Price-to-Owner-Earnings for today is 10.79.


The historical rank and industry rank for Viatris's Price-to-Owner-Earnings or its related term are showing as below:

VTRS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.03   Med: 20.51   Max: 937
Current: 10.8

During the past 13 years, the highest Price-to-Owner-Earnings of Viatris was 937.00. The lowest was 3.03. And the median was 20.51.


VTRS's Price-to-Owner-Earnings is ranked better than
85.11% of 423 companies
in the Drug Manufacturers industry
Industry Median: 27.58 vs VTRS: 10.80

As of today (2024-04-25), Viatris's share price is $11.55. Viatris's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.04. Therefore, Viatris's PE Ratio for today is 288.75.

As of today (2024-04-25), Viatris's share price is $11.55. Viatris's EPS without NRI for the trailing twelve months (TTM) ended in was $0.20. Therefore, Viatris's PE Ratio without NRI for today is 57.46.

During the past 13 years, Viatris's highest PE Ratio without NRI was 67.31. The lowest was 4.71. And the median was 10.24.


Viatris Price-to-Owner-Earnings Historical Data

The historical data trend for Viatris's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Price-to-Owner-Earnings Chart

Viatris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.85 937.00 10.93 3.76 10.13

Viatris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.76 3.31 3.73 3.41 10.13

Competitive Comparison of Viatris's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viatris's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Viatris's Price-to-Owner-Earnings falls into.



Viatris Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Viatris's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=11.55/1.07
=10.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viatris  (NAS:VTRS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Viatris Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Viatris's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Viatris (Viatris) Business Description

Address
1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Executives
Andrew Cuneo officer: See Remarks 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Xiangyang (sean) Ni officer: President, Greater China 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Leo Frans Groothuis director 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Scott Andrew Smith director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elisha W Finney director C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Van Der Meer Mohr Pauline director 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Menassie Taddese officer: See Remarks 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Robert J Coury director, officer: Executive Chairman BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
W Don Cornwell director
Brian Roman officer: Global General Counsel 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Anthony Mauro officer: See Remarks BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
James M Kilts director 120 PARK AVE, NEW YORK NY 10017
Melina E Higgins director BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
Ian C Read director PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Dillon Joellen Lyons director BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HARTFORDSHIRE X0 AL 109UL

Viatris (Viatris) Headlines

From GuruFocus

Viatris Inc's Dividend Analysis

By GuruFocus Research 11-21-2023